Companies · Biotechnology

OXOS Series #6 Holdings, LLC

ATLANTA · Biotechnology

Diligence memoA one-page analyst read on OXOS Series #6 Holdings, LLC — recommendation, valuation, rhythm, risks.→
$4.4M
Total raised · real
1
Rounds
—
Latest step-up
Top 60%
Sector rank · raised
Series A
Latest stage · inferred · Fri Feb 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

OXOS Series #6 Holdings, LLC looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.66× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 5.4 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

OXOS Series #6 Holdings, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
5.7 yr record
Peak capital year was 2021 with $4.4M across 1 filings.
Market position
ahead of 41% of Biotechnology peers
Capital scale is ahead of 41% of Biotechnology peers; modeled value is above 62% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $4.4M across 1 filings.
  • Largest single filing was $4.4M on 2021-02-05.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

OXOS Series #6 Holdings, LLC is one of 4293 Biotechnology companies tracked from ATLANTA. By capital raised it ranks mid-pack (ahead of 41% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
43
Investors (latest)
2021
Year incorporated
2021-02-05
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2021-02-05 Raised $4.4M (real) Modeled valuation $119M (est)$4.4M$119MSeries A2021

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.4M · 2021

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$119.2M
Base estimate est.
$4.8M
Conservative case
$564.6M
Upside case
$20.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
5.4 yr
Elapsed time used
5.4 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
5.7 yr
On record since
2021
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▼ 0.6× of median
This company$4.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage)▼ 0.8× of median
This company$4.4M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages)▲ 1.9× above median
This company$119.2M
Sector median$64.2M

Raised more than 41% of sector peers (real $). Modeled value above 62% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #144 of 216.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)OXOS Series #6 Holdings, LLC (this company) Raised $4.4M · modeled $119.2M (est)OXOS Series #6 Holdings, LLC
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
OXOS Series #6 Holdings, LLC this companySeries A$4.4M$119.2M0.66×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.4M2021-02-05$20.0M$119.2M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.4M2021-02-05
    • First recorded raise — entered as Series A.
    • 43 investors on this round.
Intelligence
—
Modeled next raise
$7.0M
Modeled next size est.range $4.6M–$11.3M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Joshua B. Hix—1 other2021-02
Evan B. Ruff——2021-02
Registry & provenance

OXOS Series #6 Holdings, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1847322
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Gilero Group, LLCBiotechnologySeries A$4.5M$106.8Msame sector · same stage
Telo Therapeutics, Inc.BiotechnologySeries A$4.7M$108.3Msame sector · same stage
Gravitas Medical, Inc.BiotechnologySeries A$4.7M$113.9Msame sector · same stage
Nanosphere IncBiotechnologySeries A$4.1M$147.1Msame sector · same stage
Kalgene Phamaceuticals Inc.BiotechnologySeries A$4.8M$109.8Msame sector · same stage
ValveXchange, Inc.BiotechnologySeries A$4.0M$145.5Msame sector · same stage
Q Holdings, Inc.BiotechnologySeries A$4.0M$145.3Msame sector · same stage
GenturaDx, Inc.BiotechnologySeries A$4.0M$144.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
OXOS Series #7 Holdings, LLCBiotechnologySeries A$129.2M95%
Akouos, Inc.BiotechnologySeries D+$4.3B86%
SELLAS Life Sciences Group, Inc.BiotechnologySeries B$148.8M85%
Fio CorpBiotechnologySeries A$299.4M85%
Koios Medical, Inc.BiotechnologySeries A$948K85%
Stabilux Biosciences, Inc.BiotechnologyPre-Seed$2.9M85%
Codiak BioSciences, Inc.BiotechnologySeries C$3.1B85%
BioHSV Holdings, Inc.BiotechnologySeed$33.5M85%
Frequently asked
How much funding has OXOS Series #6 Holdings, LLC raised?
OXOS Series #6 Holdings, LLC has raised approximately $4.4M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is OXOS Series #6 Holdings, LLC's estimated valuation?
Provath's modeled valuation for OXOS Series #6 Holdings, LLC is approximately $119.2M (modeled range $4.8M–$564.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is OXOS Series #6 Holdings, LLC at?
OXOS Series #6 Holdings, LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Feb 05.
What does OXOS Series #6 Holdings, LLC do and where is it based?
OXOS Series #6 Holdings, LLC operates in the Biotechnology sector, based in ATLANTA.
Explore related

See where OXOS Series #6 Holdings, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at OXOS Series #6 Holdings, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.